Bottom line
DLHAX vs FTXH: the short answer
DLHAX (Nomura Healthcare Fund) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) are both mutual funds.
But DLHAX is far broader, holding 108 positions to 51 for FTXH, so beyond the top names it adds exposure FTXH doesn't have.
FTXH is cheaper at 0.6% vs 1.21% — a difference of $61 a year per $10,000 invested.
Over five years, FTXH returned +6.5% a year vs +6.2% for DLHAX.
DLHAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
DLHAX vs FTXH side by side
| DLHAX | FTXH | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Voya | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.21% | 0.6% |
| Annual cost per $10k | $121 | $60 |
| 10-yr cost on $10k (prospectus) | $2,006 | — |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +15.1% | +24.0% |
| 5-yr return (annualized) | +6.2% | +6.5% |
| 10-yr return (annualized) | +9.5% | — |
| Best quarter | +21.5% | +18.3% |
| Worst quarter | −14.9% | −17.4% |
| Net assets (fund) | $750.2M | $36.2M |
| Number of holdings | 108 | 51 |
| Portfolio turnover | 4% | 35% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | DLHAX | FTXH | Difference |
|---|---|---|---|
| 2025 | +22.1% | +24.0% | −1.9% |
| 2024 | +8.5% | +3.0% | +5.5% |
| 2023 | +4.2% | −1.4% | +5.6% |
| 2022 | −1.3% | +2.5% | −3.8% |
| 2021 | −5.3% | +6.1% | −11.4% |
| 2020 | +11.1% | +10.9% | +0.3% |
| 2019 | +31.5% | +22.4% | +9.2% |
| 2018 | −0.8% | −8.4% | +7.5% |
| 2017 | +32.0% | +18.8% | +13.2% |
Source: Fund prospectus bar charts
Holdings overlap
13 of DLHAX's top 25 holdings also appear in FTXH's top 25.
| Holding | DLHAX | FTXH |
|---|---|---|
| Abbvie Inc | 4.19% | 7.39% |
| Eli Lilly & Company | 4.16% | 7.77% |
| Regeneron Pharmaceuticals Inc | 3.91% | 2.72% |
| Pfizer Inc | 3.84% | 2.97% |
| Merck & Company Inc | 3.68% | 7.07% |
| Gilead Sciences Inc | 3.54% | 2.89% |
| Viatris Inc | 2.48% | 3.62% |
| Halozyme Therapeutics Inc | 2.30% | 1.21% |
| Amgen Inc | 2.27% | 3.18% |
| Illumina Inc | 2.11% | 1.98% |
| Alkermes Plc | 1.82% | 1.35% |
| Vertex Pharmaceuticals Inc | 1.66% | 3.41% |
| Neurocrine Biosciences Inc | 1.57% | 1.37% |
Source: SEC Form N-PORT
DLHAX top 10
- Ucb Sa — 5.19%
- Abbvie Inc — 4.19%
- Eli Lilly & Company — 4.16%
- Regeneron Pharmaceuticals Inc — 3.91%
- Unitedhealth Group Inc — 3.88%
- Pfizer Inc — 3.84%
- Merck & Company Inc — 3.68%
- Gilead Sciences Inc — 3.54%
- Astrazeneca Plc — 3.27%
- Elevance Health Inc — 3.25%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between DLHAX and FTXH?
Which is cheaper, DLHAX or FTXH?
Should I own both DLHAX and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.